Comparative metabolic safety of efavirenz-, dolutegravir-, and bictegravir-based antiretroviral regimens in HIV-infected adults: Evidence for weight-dependent lipid deterioration

Junzhong Ma; Chen Lu; Ruiying Xu; Zere Aidynbek; Yuanyuan Wan; Bufeng Qi; Yide Xu; Yiting Shao; Yuanyuan Xu; Jingwen Wang; Shengxian Wu; Zhengping Zhu; Shanshan Geng

doi:10.1016/j.jiph.2026.103293

Q1 2026

Comparative metabolic safety of efavirenz-, dolutegravir-, and bictegravir-based antiretroviral regimens in HIV-infected adults: Evidence for weight-dependent lipid deterioration

Junzhong Ma · Chen Lu · Ruiying Xu · Zere Aidynbek · Yuanyuan Wan · Bufeng Qi · Yide Xu · Yiting Shao · Yuanyuan Xu · Jingwen Wang · Shengxian Wu · Zhengping Zhu · Shanshan Geng

10.1016/j.jiph.2026.103293 384 Views 0 Citations

Citations

384

Views

Abstract not available for this publication.

Cite this Article (APA)

Junzhong, M., Chen, L., Ruiying, X., Zere, A., Yuanyuan, W., Bufeng, Q., Yide, X., Yiting, S., Yuanyuan, X., Jingwen, W., Shengxian, W., Zhengping, Z., Shanshan, G. (2026). Comparative metabolic safety of efavirenz-, dolutegravir-, and bictegravir-based antiretroviral regimens in HIV-infected adults: Evidence for weight-dependent lipid deterioration. Journal of Infection and Public Health. https://doi.org/10.1016/j.jiph.2026.103293